July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
UPARANT is an effective antiangiogenic in a novel mouse model of rubeosis iridis associated with neovascular glaucoma
Author Affiliations & Notes
  • Helder Andre
    St Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden
  • Filippo Locri
    St Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden
    Dept. Biology, University of Pisa, Pisa, Italy
  • Monica Aronsson
    St Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden
  • Maurizio Cammalleri
    Dept. Biology, University of Pisa, Pisa, Italy
  • Massimo Dal Monte
    Dept. Biology, University of Pisa, Pisa, Italy
  • Paola Bagnoli
    Dept. Biology, University of Pisa, Pisa, Italy
  • Mario De Rosa
    Dept. Experimental Medicine, Second University of Napoli, Naples, Italy
  • Vincenzo Pavone
    Dept. Chemical Sciences, University of Napoli Federico II, Naples, Italy
  • Anders P Kvanta
    St Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden
  • Footnotes
    Commercial Relationships   Helder Andre, None; Filippo Locri, None; Monica Aronsson, None; Maurizio Cammalleri, None; Massimo Dal Monte, None; Paola Bagnoli, None; Mario De Rosa, Kaleyde Pharmaceuticals AG (I), Kaleyde Pharmaceuticals AG (P), Kaleyde Pharmaceuticals AG (S); Vincenzo Pavone, Kaleyde Pharmaceuticals AG (P), Kaleyde Pharmaceuticals AG (S); Anders Kvanta, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1251. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Helder Andre, Filippo Locri, Monica Aronsson, Maurizio Cammalleri, Massimo Dal Monte, Paola Bagnoli, Mario De Rosa, Vincenzo Pavone, Anders P Kvanta; UPARANT is an effective antiangiogenic in a novel mouse model of rubeosis iridis associated with neovascular glaucoma. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1251.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Puncture-induced iris wound healing in mice is associated with upregulation of inflammatory factors and iris neovascularization (rubeosis iridis; NVI). Here, we investigate the anti-angiogenic and anti-inflammatory effectiveness of UPARANT in a new model of rubeosis iridis associated with neovascular glaucoma (NVG).

Methods : BALB/c mouse pups of either sex were subjected to uveal puncture to stimulate NVI or injected with ARPE-19 hypoxia-conditioned media to mimic NVG. UPARANT effectiveness in reducing NVI and NVG was determined by noninvasive in vivo iris vascular densitometry, and confirmed in vitro by quantitative vascular-specific CD31 immunostaining. Angiogenic and inflammatory related factors were assayed by quantitative PCR at the transcript level and by semi-quantitative western blot at the protein level.

Results : Our data comparatively analyses antiangiogenic effects UPARANT to a mouse equivalent of aflibercept (VEGFR1 Fc chimera). Intravitreal administration of UPARANT successfully and rapidly reduced iris vasculature to control (non-induced) level, in both NVI and NVG models, while VEGFR1 Fc chimera displays a slower antiangiogenic effect that is not reduced to control levels. Molecular analysis revealed that UPARANT antagonizes formyl peptide receptors (FPR) through a predominantly anti-inflammatory response, accompanied with significant reduction of IL1β, IL6, CXCR4, CCL2, MMP2, MMP9, PAI-1, and uPAR. Furthermore, similar results were observed when UPARANT was administered systemically by subcutaneous injection.

Conclusions : The multitarget peptide UPARANT is superior to anti-VEGF in the treatment of NVI and rubeosis iridis associated with NVG in this novel mouse model. In addition, UPARANT displayed systemic effectiveness in reducing both NVI and NVG, which could provide improved therapy and compliance for proliferative ocular diseases.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×